By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia today said it is postponing its planned initial public offering, citing unfavorable market conditions.

In a statement, the molecular diagnostics firm said that its planned offering coincides with an "extraordinarily volatile period in global capital markets resulting in high levels of uncertainty and volatility that do not meet the existing shareholders' and the company's desire to achieve a successful IPO with an orderly aftermarket."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.